These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30594188)

  • 1. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
    Baek JS; Yu JJ; Kim MJ; You J; Jun HO; Kim YH; Ko JK
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):83. PubMed ID: 30594188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection.
    Dionne A; Le CK; Poupart S; Autmizguine J; Meloche-Dumas L; Turgeon J; Fournier A; Dahdah N
    PLoS One; 2018; 13(10):e0206001. PubMed ID: 30332473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML; Manlhiot C; Collins TH; Chahal N; Yeung RSM; McCrindle BW
    Int J Cardiol; 2017 Jun; 236():157-161. PubMed ID: 28089146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
    Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decision tree model for predicting intravenous immunoglobulin resistance and coronary artery involvement in Kawasaki disease.
    Joung J; Oh JS; Yoon JM; Ko KO; Yoo GH; Cheon EJ
    BMC Pediatr; 2022 Aug; 22(1):474. PubMed ID: 35931986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
    Downie ML; Manlhiot C; Latino GA; Collins TH; Chahal N; Yeung RS; McCrindle BW
    J Pediatr; 2016 Dec; 179():124-130.e1. PubMed ID: 27659027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of 2 diagnostic criteria of echocardiography for coronary artery aneurysm in Kawasaki disease].
    Liu WQ; Xia B; Fan W; Yu Z; Lin WL; Chen L; Wang C; Liu BN; Li J; Yang J
    Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):588-593. PubMed ID: 35658368
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement.
    Li DT; Yang Q; Xia CY; Zhang YF; Cai Y; Wu SQ; Jiang Q; Hu P
    Clin Exp Med; 2024 Aug; 24(1):177. PubMed ID: 39105936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
    Zhang H; Cai J; Zhang R; Shuai S; Tang M; Ju R; Hu Y; Zuo T; Yang Y
    J Int Med Res; 2024 May; 52(5):3000605241252115. PubMed ID: 38713460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.